A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1199-1206

  Zhi, Jianguo ^a   Chen, Eric ^b   Major, Pierre ^c   Burns, Ivon ^d   Robinson, Bridget ^e   McKendrick, Joe ^f   Rittweger, Karen ^a   Abt, Markus ^h   Goldstein, David ^g  

^a HOFFMANN LA ROCHE INC   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d ST VINCENT S HOSPITAL   (Australia)

^e CHRISTCHURCH HOSPITAL   (New Zealand)

^f BOX HILL HOSPITAL   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bevacizumab; FOLFOX 4; Pharmacokinetics; XELOX

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 82455205853     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1606-z     Document Type: Article

References (13)

1. A Jemal R Siegel E Ward, et al. 2009 Cancer statistics, 2009 CA Cancer J Clin 59 225 249 19474385 10.3322/caac.20006
2. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P, Meta-Analysis Group in Cancer (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22(18):3766-3775. Erratum in: J Clin Oncol. 2005 Feb 20; 23(6):1337-1338 (Pubitemid 41095217)
3. JJ Lokich JD Ahlgren JJ Gullo JA Philips JG Fryer 1989 A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study J Clin Oncol 7 4 425 432 2926468 1:STN:280:DyaL1M7nslChsQ%3D%3D (Pubitemid 19098135)
4. RM Hansen 1991 5-Fluorouracil by protracted venous infusion: a review of recent clinical studies Cancer Invest 9 6 637 642 1747791 10.3109/ 07357909109039875 1:STN:280:DyaK38%2Fotleksw%3D%3D
5. GV Koukourakis V Kouloulias MJ Koukourakis GA Zacharias H Zabatis J Kouvaris 2008 Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review Molecules 13 8 1897 1922 18794792 10.3390/molecules13081897 1:CAS:528:DC%2BD1cXhtFamsbbF
6. A de Gramont A Figer M Seymour, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 10944126 (Pubitemid 30644117)
7. ®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumor Ann Oncol 13 558 565 12056706 10.1093/annonc/mdf065 1:STN:280:DC%2BD38zhsVynsQ%3D%3D (Pubitemid 34461139)
8. HT Arkenau D Arnold J Cassidy E Diaz-Rubio JY Douillard H Hochster A Martoni A Grothey A Hinke W Schmiegel HJ Schmoll R Porschen 2008 Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials J Clin Oncol 26 36 5910 5917 19018087 10.1200/JCO.2008.16.7759 1:CAS:528: DC%2BD1MXhs1GgurY%3D Epub 2008 Nov 17
9. J Cassidy S Clarke E Díaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzén L Saltz 2008 Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 12 2006 2012 18421053 10.1200/JCO.2007.14.9898 1:CAS:528:DC%2BD1cXlvFaqs7s%3D
10. Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors Trial (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25(27):4224-4230. Epub 2007 Jun 4
11. H Hurwitz 2004 Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer Clin Colorectal Cancer 4 S62 S68 15479481 10.3816/CCC.2004.s.010 1:CAS:528:DC%2BD2cXpslOmtb8%3D
12. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
13. JF Lu R Bruno S Eppler W Novotny B Lum J Gaudreault 2008 Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother Pharmacol 62 5 779 786 18205003 10.1007/s00280-007-0664-8 1:CAS:528: DC%2BD1cXht1CjtL3E